Moh’d Khushman, MD

Articles by Moh’d Khushman, MD

Dr Khushman on the Rationale for Investigating INCA33890 in MSS/pMMR mCRC

September 28th 2026

Moh’d Khushman, MD, discusses the rationale for investigating INCA33890 plus FOLFOX/bevacizumab in the phase 3 setting in patients with MSS/pMMR mCRC.

Dr. Khushman on Best Practices in the Management of GI Cancers

ByMoh’d Khushman, MD

January 7th 2022

Moh’d Khushman, MD, discusses best practices in the management of gastrointestinal cancers.

Moh’d Khushman, MD

Articles by Moh’d Khushman, MD

Dr Khushman on the Rationale for Investigating INCA33890 in MSS/pMMR mCRC

Dr. Khushman on Best Practices in the Management of GI Cancers

Latest Updated Articles

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer

September Roundup of FDA Approvals in Oncology: 8 Decisions to Know

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Individualized Neoantigen Vaccine Elicits Durable T-Cell Responses in Resected HPV– HNSCC